CareDx Hybrid Capture Tech for HLA Testing Receives CE Marking
The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.
CareDx Q1 Revenues Up 21 Percent
The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.
CareDx Licenses Illumina NGS Transplant Clinical Application Products
CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.